- Home
- ZVIA vs LPCN Comparison
ZVIA vs LPCN Comparison
Compare ZVIA & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVIA
- LPCN
- Stock Information
- Founded
- ZVIA 2007
- LPCN 1997
- Country
- ZVIA United States
- LPCN United States
- Employees
- ZVIA N/A
- LPCN N/A
- Industry
- ZVIA Beverages (Production/Distribution)
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- ZVIA Consumer Staples
- LPCN Health Care
- Exchange
- ZVIA Nasdaq
- LPCN Nasdaq
- Market Cap
- ZVIA 65.0M
- LPCN 36.8M
- IPO Year
- ZVIA 2021
- LPCN N/A
- Fundamental
- Price
- ZVIA $1.11
- LPCN $5.46
- Analyst Decision
- ZVIA Hold
- LPCN Strong Buy
- Analyst Count
- ZVIA 4
- LPCN 1
- Target Price
- ZVIA $1.56
- LPCN $10.00
- AVG Volume (30 Days)
- ZVIA 110.7K
- LPCN 23.4K
- Earning Date
- ZVIA 11-05-2024
- LPCN 11-06-2024
- Dividend Yield
- ZVIA N/A
- LPCN N/A
- EPS Growth
- ZVIA N/A
- LPCN N/A
- EPS
- ZVIA N/A
- LPCN N/A
- Revenue
- ZVIA $160,108,000.00
- LPCN $4,800,930.00
- Revenue This Year
- ZVIA N/A
- LPCN N/A
- Revenue Next Year
- ZVIA $10.43
- LPCN N/A
- P/E Ratio
- ZVIA N/A
- LPCN N/A
- Revenue Growth
- ZVIA N/A
- LPCN 8630.55
- 52 Week Low
- ZVIA $0.62
- LPCN $2.31
- 52 Week High
- ZVIA $2.42
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- ZVIA 52.18
- LPCN 61.75
- Support Level
- ZVIA $1.05
- LPCN $4.89
- Resistance Level
- ZVIA $1.17
- LPCN $5.85
- Average True Range (ATR)
- ZVIA 0.06
- LPCN 0.38
- MACD
- ZVIA -0.00
- LPCN 0.04
- Stochastic Oscillator
- ZVIA 42.50
- LPCN 64.83
About ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.